CSF-1 AND ITS RECEPTOR IN OVARIAN, ENDOMETRIAL AND BREAST-CANCER
CSF-1 AND ITS RECEPTOR IN OVARIAN, ENDOMETRIAL AND BREAST-CANCER
复制标题
DOI：
10.3109/07853899509031941
复制
发表时间：
1995-02-01
影响因子：
4.4
通讯作者：
KACINSKI, BM
中科院分区：
文献类型：
--
作者：
KACINSKI, BM
本文就CSF-I及其受体在乳腺和女性生殖道肿瘤中的作用作一综述。在人乳腺、卵巢和子宫内膜的肿瘤中研究了CSF-1及其受体的表达和功能，CSF-1及其受体最初被认为是正常单核细胞发育和滋养层植入所必需的，最近已显示在乳腺癌中表达，卵巢和子宫内膜，其中受体被肿瘤细胞或基质成分产生的配体激活，刺激肿瘤细胞通过尿激酶侵袭，依赖机制乳腺癌表达野生型CSF-1受体，其水平与滋养层和单核细胞中观察到的水平相当。卵巢癌和子宫内膜癌表达明显较低水平的野生型、功能性CSF-1 R，而卵巢癌还表达在其5'胞外和其它序列中与野生型CSF-1 R转录物不同的不寻常转录物。CSF-1 R的肿瘤细胞表达受几种类固醇激素（糖皮质激素和孕激素）的控制，并且肿瘤细胞CSF-1表达似乎受其他激素的调节，其中一些激素参与正常的催乳分化。此外，肿瘤细胞通常以如此高的水平产生CSF-1，使得CSF-1溢出到细胞外液和循环中。事实证明，测量循环中的CSF-1水平对于卵巢癌、子宫内膜癌和乳腺癌患者的疾病检测和治疗反应监测都是有用的。CSF-1及其受体似乎是乳腺癌和女性生殖道肿瘤生物学中的重要受体/配体对，其中它们可以调节与它们在巨噬细胞活化和胎盘植入期间控制的功能类似的功能。
The aim of this report is to review the role of CSF-I and its receptor in neoplasms of the breast and female reproductive tract. Expression and function of CSF-1 and its receptor were studied in tumours of the human breast, ovary and endometrium, CSF-1 and its receptor, initially implicated as essential to normal monocyte development and trophoblastic implantation, have been more recently shown to be expressed by carcinomas of the breast, ovary and endometrium where activation of the receptor by ligand produced either by the tumour cells or by stromal elements stimulates tumour cell invasion by a urokinase-dependent mechanism. Breast carcinomas express wildtype CSF-1 receptors at levels comparable to those observed in trophoblast and monocytes. Ovarian and endometrial carcinomas express significantly lower levels of wild-type, functional CSF-1Rs while ovarian carcinomas also express unusual transcripts which diverge from the wild-type CSF-1R transcript in their 5' extracellular and other sequences. Tumour cell expression of CSF-1R is under the control of several steroid hormones (glucocorticoids and progestins) and tumour cell CSF-1 expression appears to be regulated by other hormones, some of which are involved in normal lactogenic differentiation. In addition, tumour cells often produce CSF-1 at such high levels that CSF-I spills into the extracellular fluid and circulation. Measurements of circulating levels of CSF-1 have proved useful in patients with ovarian, endometrial and breast carcinoma patients both for disease detection and monitoring of response to therapy. CSF-1 and its receptor appear to be an important receptor/ligand pair in the biology of breast cancers and tumours of the female reproductive tract where they may regulate functions similar to those which they control during macrophage activation and placental implantation.